Skip to main content

Table 2 Multivariable hazard ratios (HR) and 95% confidence interval (95%CI) of overall and breast cancer-specific mortality according to the adherence to the Mediterranean diet measured by the arMED score

From: Association of Mediterranean diet with survival after breast cancer diagnosis in women from nine European countries: results from the EPIC cohort study

 

Categories of adherence of the arMED scorea

arMED score, continuous

Low

Medium

High

3-units increase

Overall mortality

 All BC survivorsb

1.13 (1.01–1.26)

1.00 reference

0.94 (0.84–1.05)

0.92 (0.87–0.97)

  N (deaths)

3427 (736)

5162 (871)

4681 (733)

13,270 (2340)

 Premenopausal BC survivorsc,d

1.21 (0.94–1.56)

1.00 reference

1.11 (0.89–1.38)

0.94 (0.84–1.06)

  N (deaths)

613 (131)

1152 (183)

1305 (213)

3070 (527)

 Postmenopausal BC survivorsc,e

1.10 (0.98–1.24)

1.00 reference

0.89 (0.78–1.01)

0.92 (0.86–0.98)

  N (deaths)

2814 (605)

4010 (688)

3376 (520)

10,200 (1813)

P value heterogeneity*

   

0.437

BC-specific mortality

 All BC survivorsb

1.12 (0.98–1.29)

1.00 reference

0.99 (0.86–1.13)

0.97 (0.90–1.04)

  N (deaths)

3427 (441)

5162 (541)

4681 (493)

13,270 (1475)

 Premenopausal BC survivorsc,d

1.23 (0.92–1.63)

1.00 reference

1.16 (0.91–1.48)

0.97 (0.85–1.11)

  N (deaths)

613 (103)

1152 (145)

1305 (180)

3070 (428)

 Postmenopausal BC survivorse

1.10 (0.94–1.28)

1.00 reference

0.93 (0.78–1.09)

0.97 (0.89–1.05)

  N (deaths)

2814 (338)

4010 (396)

3376 (313)

10,200 (1047)

P value heterogeneity*

   

0.992

  1. Abbreviations: arMED Adapted relative Mediterranean diet, N Number of breast cancer cases
  2. aCategories of arMED: low adherence, 0–5; medium adherence, 6–8; high adherence, 9–16
  3. bModel stratified by country, stage (metastatic, non-metastatic, unknown) and menopausal status at diagnosis and adjusted for age at diagnosis, attained level of education, physical activity, body mass index (modeled as restricted cubic spline), alcohol consumption reported at recruitment, smoking habit and intensity at recruitment, ever use of hormones for menopause at diagnosis, grade of differentiation, and tumor receptor status (ER, PR, HER2)
  4. cSame model as above without stratification for menopausal status al diagnosis
  5. dModel premenopause: variable age into 2 categories, < 50 and >  = 50, and not adjusted for every use of hormone therapy replacement for menopause
  6. eModel postmenopause: variable age into 2 categories, < 65 and >  = 65
  7. *Pvalue for heterogeneity between pre- and postmenopausal subgroups for the association of arMED and mortality outcomes